Q4 2024 Earnings Call Transcript March 27, 2025 ADC Therapeutics SA beats earnings expectations. Reported EPS is $-0.29, ...

Discover key insights from ADC Therapeutics' Q4 2024 earnings call, including ZYNLONTA’s commercial success, clinical trial updates, and strategic ...

We made significant progress in advancing our strategy to expand the use of ZYNLONTA into earlier lines of DLBCL and indolent lymphomas. December included completion of enrollment in our pivotal ...

Bristol Myers Squibb gets European Commission approval to expand use of CAR T cell therapy, Breyanzi for relapsed or refractory follicular lymphoma: Princeton, New Jersey Monday, ...

SUV remains the most widely used PET parameter to evaluate NHLs because it is directly associated with lymphoma aggressiveness.

Bristol-Myers Squibb (NYSE:BMY) recently gained European Commission approval for Breyanzi, broadening treatment options for indolent non-Hodgkin lymphoma, which was a significant recent event. During ...

Reports Q4 revenue $16.4M vs. $16.6M last year. “We achieved several key milestones in 2024, advancing our expansion trials with Zynlonta in ...

SUZHOU, China, March 27, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today reported 2024 annual ...

SMZL is a type of lymphoma that affects the spleen, splenic hilar lymph nodes, bone marrow, and peripheral blood. Patients with SMZL often experience lymphocytosis and cytopenias, such as anemia and ...